- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Denali Therapeutics Inc (DNLI)
Denali Therapeutics Inc stock price live, this page displays NASDAQ DNLI stock exchange data. View the DNLI premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Denali Therapeutics Inc real time stock price chart below.
What Is the Denali Therapeutics Inc Stock Price Today?
The Denali Therapeutics Inc stock price today is 13.87.
What Is the Stock Symbol for Denali Therapeutics Inc?
The stock symbol for Denali Therapeutics Inc is ""DNLI.""
What Stock Exchange Does Denali Therapeutics Inc Trade On?
Denali Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Denali Therapeutics Inc a Good Stock to Buy?
Determining whether Denali Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the DNLI quote. (ISIN: US24823R1059)
What Is the Denali Therapeutics Inc Stock Price Today?
The Denali Therapeutics Inc stock price today is 13.87.
What Is the Stock Symbol for Denali Therapeutics Inc?
The stock symbol for Denali Therapeutics Inc is ""DNLI.""
What Stock Exchange Does Denali Therapeutics Inc Trade On?
Denali Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Denali Therapeutics Inc a Good Stock to Buy?
Determining whether Denali Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the DNLI quote. (ISIN: US24823R1059)
13.87
+0.04(+0.29%)
Closed·
After Hours
13.870.00(0.00%)
·
Fair Value
An estimate of a Denali Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
13.70
14.10
52 wk Range
10.57
33.33
DNLI Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Earnings results expected in 8 days
More Info
Fair Value
An estimate of a Denali Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
13.7014.10
52 wk Range
10.5733.33
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
DNLI Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Denali Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
32.19
Upside
+132.07%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
5 analysts have revised their earnings upwards for the upcoming period
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Denali Therapeutics Inc Company Profile
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; DNL343 eIF2B activator program for amyotrophic lateral sclerosis; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson’s and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company’s OTV programs also comprise DNL628 targeting tau for Alzheimer’s disease; and DNL422 targeting alpha synuclein for Parkinson’s disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer’s disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
Compare DNLI to Peers and Sector
Metrics to compare | DNLI | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipDNLIPeersSector | |
|---|---|---|---|---|
P/E Ratio | −4.4x | −0.5x | −0.5x | |
PEG Ratio | 0.03 | 0.00 | 0.00 | |
Price/Book | 1.8x | 1.8x | 2.6x | |
Price / LTM Sales | - | 8.3x | 3.2x | |
Upside (Analyst Target) | 124.2% | 186.1% | 42.7% | |
Fair Value Upside | Unlock | 19.6% | 5.8% | Unlock |
Analyst Ratings
19 Buy
0 Hold
0 Sell
Ratings:
19 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 32.19
(+132.07% Upside)
Earnings
Latest Release
May 06, 2025
EPS / Forecast
-0.78 / -0.70
Revenue / Forecast
-- / 1.70M
People Also Watch
FAQ
What Stock Exchange Does Denali Therapeutics Trade On?
Denali Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Denali Therapeutics?
The stock symbol for Denali Therapeutics is "DNLI."
What Is the Denali Therapeutics Market Cap?
As of today, Denali Therapeutics market cap is 2.01B.
What Is Denali Therapeutics's Earnings Per Share (TTM)?
The Denali Therapeutics EPS (TTM) is -2.67.
When Is the Next Denali Therapeutics Earnings Date?
Denali Therapeutics will release its next earnings report on 30 Jul 2025.
From a Technical Analysis Perspective, Is DNLI a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Denali Therapeutics Stock Split?
Denali Therapeutics has split 0 times.
How Many Employees Does Denali Therapeutics Have?
Denali Therapeutics has 443 employees.
What is the current trading status of Denali Therapeutics (DNLI)?
As of 23 Jul 2025, Denali Therapeutics (DNLI) is trading at a price of 13.87, with a previous close of 13.87. The stock has fluctuated within a day range of 13.70 to 14.10, while its 52-week range spans from 10.57 to 33.33.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.